Latest Chloride channel Stories
BOULDER, Colo., Nov. 19, 2014 /PRNewswire/ -- N30 Pharmaceuticals, Inc.
ChanTest’s expertise will be showcased at the North American Cystic Fibrosis Conference this month, highlighting the important research the company has conducted to help move cystic fibrosis
The study, led by Martina Gentzsch, PhD, provides evidence that could help drug developers improve compounds aimed at correcting CFTR proteins in cystic fibrosis patients.
BOULDER, Colo., March 12, 2014 /PRNewswire/ -- N30 Pharmaceuticals, Inc. ("N30 Pharma") announced today that it has begun oral dosing of N91115 in a Phase 1 clinical trial.
A little more than a year after the FDA approved Kalydeco (Vx-770), the first drug of its kind to treat the underlying cause of cystic fibrosis, University of Missouri researchers believe they have found exactly how this drug works and how to improve its effectiveness in the future.
A recent study led by Gergely Lukacs, a professor at McGill University's Faculty of Medicine, Department of Physiology, and published in the January issue of Cell, has shown that restoring normal function to the mutant gene product responsible for cystic fibrosis (CF) requires correcting two distinct structural defects.
Cystic fibrosis (CF), a chronic disease that clogs the lungs and leads to life-threatening lung infections, is caused by a genetic defect in a chloride channel called cystic fibrosis transmembrane conductase regulator (CFTR).
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease.
An investigational drug targeting a defective protein that causes cystic fibrosis has been shown to improve lung function in a small study of CF patients.
- Emitting flashes of light; glittering.